Last10K.com

Pear Therapeutics, Inc. (PEAR) SEC Filing S-1 IPO Report

SEC Filings

PEAR Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

PEAR Annual Reports

PEAR Quarterly Reports

PEAR Corporate News

PEAR Registration of Securities

  • S-1 Registration of Securities December 2021

Pear Therapeutics, Inc.

HISTORY TOOLS
CIK: 1835567 Ticker: PEAR

View differences made from one to another to evaluate Pear Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this S-1 Registration of Securities to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Pear Therapeutics, Inc..

Continue

Assess how Pear Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Pear Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this S-1 Registration of Securities

Cover
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statement Of Cash Flows
Condensed Consolidated Statement Of Changes In Stockholders' (Deficit) Equity
Condensed Consolidated Statement Of Changes In Stockholders' Equity- Thimble (Parenthetical)
Condensed Consolidated Statements Of Operations
Condensed Consolidated Statements Of Operations- Thimble (Parenthetical)
Consolidated Balance Sheets 10K
Consolidated Balance Sheets 10K (Parenthetical)
Consolidated Balance Sheets 10Q
Consolidated Balance Sheets 10Q (Parenthetical)
Consolidated Statements Of Operations And Comprehensive Loss
Unaudited Condensed Consolidated Statements Of Cash Flows
Unaudited Condensed Consolidated Statements Of Convertible Preferred Stock And Stockholders??? Deficit
Unaudited Condensed Consolidated Statements Of Convertible Preferred Stock And Stockholders??? Deficit (Parenthetical)
Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities (Details)
Accrued Expenses And Other Current Liabilities (Tables)
Collaboration And License Agreements
Collaboration And License Agreements (Tables)
Collaboration And License Agreements - Change In Deferred Revenue (Details)
Collaboration And License Agreements - Novartis (Details)
Collaboration And License Agreements - Sandoz (Details)
Collaboration And License Agreements - Sandoz Note Payable (Details)
Commitments
Commitments - Additional Information (Detail)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Narrative (Details)
Commitments And Contingencies - Operating Leases (Details)
Common Stock
Common Stock (Details)
Common Stock (Tables)
Convertible Preferred Stock
Convertible Preferred Stock (Details)
Convertible Preferred Stock (Tables)
Description Of Organization And Business Operations
Description Of Organization And Business Operations - Additional Information (Details)
Fair Value Measurements
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements (Tables)
Fair Value Measurements - Additional Information (Detail)
Fair Value Measurements - Assets And Fair Value (Details)
Fair Value Measurements - Level 3 Roll Forward (Details)
Fair Value Measurements - Narrative (Details)
Fair Value Measurements - Schedule Of Quantitative Information Regarding Level 3 Fair Value Measurements (Detail)
Fair Value Measurements - Summary Of Assets And Liabilities That Are Measured At Fair Value On A Recurring Basis (Detail)
Fair Value Measurements - Summary Of Changes In The Fair Value Of Warrant Liabilities (Detail)
Fair Value Measurements - Valuation Assumptions (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Details)
Income Taxes - Deferred Tax Assets (Details)
Income Taxes - Reconciliation Of Tax Rate (Details)
Indebtedness
Indebtedness (Tables)
Indebtedness - Future Minimum Payments Due (Details)
Indebtedness - Perceptive Credit Facility (Details)
Indebtedness - Schedule Of Debt (Details)
Indebtedness - Svb Term Loan (Details)
Initial Public Offering
Initial Public Offering - Additional Information (Detail)
License Agreements
License Agreements (Details)
Nature Of Business
Nature Of Business - Narrative (Details)
Nature Of Business - Organization (Details)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Antidilituve Securities (Details)
Net Loss Per Share - Basic And Diluted Per Share (Details)
Private Placement
Private Placement - Additional Information (Detail)
Property And Equipment
Property And Equipment (Details)
Property And Equipment (Tables)
Related Party Transactions
Related Party Transactions (Tables)
Related Party Transactions - Additional Information (Detail)
Related Party Transactions - Schedule Of Quantitative Information Regarding Fair Value Measurements Of Promissory Note (Detail)
Related-Party Transactions
Related-Party Transactions (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Common Stock Options (Details)
Stock-Based Compensation - Narrative (Details)
Stock-Based Compensation - Stock Based Compensation Expense (Details)
Stock-Based Compensation - Valuation Assumptions (Details)
Stockholder's Equity
Stockholder's Equity - Additional Information (Detail)
Subsequent Events
Subsequent Events
Subsequent Events (Details)
Subsequent Events- Thimble (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Details)
Summary Of Significant Accounting Policies - Cash, Cash Equivalents And Restricted Cash (Details)
Summary Of Significant Accounting Policies - Narrative (Details)
Summary Of Significant Accounting Policies - Property And Equipment (Details)
Summary Of Significant Accounting Policies - Summary Of Basic And Diluted Net Income (Loss) Per Common Share (Details)
Summary Of Significant Accounting Policies - Summary Of Class A Common Stock Subject To Possible Redemption (Details)
Warrants
Warrants - Additional Information (Detail)

Material Contracts, Statements, Certifications & more

Pear Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 5.1: Opinion Regarding Legality
Exhibit 10.26: Material Contract
Exhibit 23.1: Consents Of Experts And Counsel
Exhibit 23.2: Consents Of Experts And Counsel
Ticker: PEAR
CIK: 1835567
Form Type: S-1 Registration of Securities
Accession Number: 0001628280-21-025559
Submitted to the SEC: Thu Dec 23 2021 4:38:33 PM EST
Accepted by the SEC: Thu Dec 23 2021
Industry: Health Services

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/pear/0001628280-21-025559.htm